A 2-year prospective follow-up study of the course of obsessive-compulsive disorder

Journal of Clinical Psychiatry

Volumn 71, Issue 8, 2010, Pages 1033-1039

  Eisen, Jane L ^a   Pinto, Anthony ^a,b,c   Mancebo, Maria C ^a,d   Dyck, Ingrid R ^a   Orlando, Maria E ^a   Rasmussen, Steven A ^a,d  

^a BROWN UNIVERSITY   (United States)

^b Columbia University ^*  (United States)

^c NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^d BUTLER HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; CLOMIPRAMINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SERTRALINE;

ADULT; ARTICLE; CLINICAL EVALUATION; COGNITIVE THERAPY; COMORBIDITY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; RECURRENT DISEASE; REMISSION;

ADULT; COGNITIVE THERAPY; COMORBIDITY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; OBSESSIVE-COMPULSIVE DISORDER; OUTCOME ASSESSMENT (HEALTH CARE); PROBABILITY; PROGNOSIS; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 77955985805     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.08m04806blu     Document Type: Article

References (47)

1. Marks IM, Hodgson R, Rachman S. Treatment of chronic obsessive-compulsive neurosis by in-vivo exposure: a two-year follow-up and issues in treatment. Br J Psychiatry. 1975;127(4):349-364.
2. O'Sullivan G, Noshirvani H, Marks I, et al. Six-year follow-up after exposure and clomipramine therapy for obsessive compulsive disorder. J Clin Psychiatry. 1991;52(4):150-155.
3. Mindus P, Rasmussen SA, Lindquist C. Neurosurgical treatment for refractory obsessive-compulsive disorder: implications for understanding frontal lobe function. J Neuropsychiatry Clin Neurosci. 1994;6(4):467-477.
4. Alonso P, Menchon JM, Pifarre J, et al. Long-term follow-up and predictors of clinical outcome in obsessive-compulsive patients treated with serotonin reuptake inhibitors and behavioral therapy. J Clin Psychiatry. 2001;62(7):535-540.
5. van Oppen P, van Balkom AJ, de Haan E, et al. Cognitive therapy and exposure in vivo alone and in combination with fluvoxamine in obsessive-compulsive disorder: a 5-year follow-up. J Clin Psychiatry. 2005;66(11):1415-1422.
6. Mawson D, Marks IM, Ramm L. Clomipramine and exposure for chronic obsessive-compulsive rituals, III: two year follow-up and further findings. Br J Psychiatry. 1982;140(1):11-18.
7. Goisman RM, Rogers MP, Steketee GS, et al. Utilization of behavioral methods in a multicenter anxiety disorders study. J Clin Psychiatry. 1993;54(6):213-218.
8. Hasin DS, Tsai WY, Endicott J, et al. Five-year course of major depression: effects of comorbid alcoholism. J Affect Disord. 1996;41(1):63-70.
9. Coryell W, Leon A, Winokur G, et al. Importance of psychotic features to long-term course in major depressive disorder. Am J Psychiatry. 1996;153(4):483-489.
10. Keller MB, Lavori PW, Klerman GL, et al. Low levels and lack of predictors of somatotherapy and psychotherapy received by depressed patients. Arch Gen Psychiatry. 1986;43(5):458-466.
11. Keller MB, Lavori PW, Mueller TI, et al. Time to recovery, chronicity, and levels of psychopathology in major depression: a 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry. 1992;49(10):809-816.
12. Goodwin DW, Guze SB, Robins E. Follow-up studies in obsessional neurosis. Arch Gen Psychiatry. 1969;20(2):182-187.
13. Skoog G, Skoog I. A 40-year follow-up of patients with obsessivecompulsive disorder [see comments]. Arch Gen Psychiatry. 1999;56(2):121-127.
14. Steketee G, Eisen J, Dyck I, et al. Predictors of course in obsessive-compulsive disorder. Psychiatry Res. 1999;89(3):229-238.
15. Eisen JL, Goodman WK, Keller MB, et al. Patterns of remission and relapse in obsessive-compulsive disorder: a 2-year prospective study. J Clin Psychiatry. 1999;60(5):346-351, quiz 352.
16. Orloff LM, Battle MA, Baer L, et al. Long-term follow-up of 85 patients with obsessive-compulsive disorder. Am J Psychiatry. 1994;151(3):441-442.
17. Catapano F, Perris F, Masella M, et al. Obsessive-compulsive disorder: a 3-year prospective follow-up study of patients treated with serotonin reuptake inhibitors OCD follow-up study. J Psychiatr Res. 2006;40(6):502-510.
18. Reddy YC, D'Souza SM, Shetti C, et al. An 11- to 13-year follow-up of 75 subjects with obsessive-compulsive disorder. J Clin Psychiatry. 2005;66(6):744-749.
19. Tukel R, Oflaz SB, Ozyildirim I, et al. Comparison of clinical characteristics in episodic and chronic obsessive-compulsive disorder. Depress Anxiety. 2007;24(4):251-255.
20. Mataix-Cols D, Rauch SL, Manzo PA, et al. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder. Am J Psychiatry. 1999;156(9):1409-1416.
21. Kempe PT, van Oppen P, de Haan E, et al. Predictors of course in obsessive-compulsive disorder: logistic regression versus Cox regression for recurrent events. Acta Psychiatr Scand. 2007;116(3):201-210.
22. Eisen JL, Rasmussen SA, Phillips KA, et al. Insight and treatment outcome in obsessive-compulsive disorder. Compr Psychiatry. 2001;42(6):494-497.
23. Pinto A, Mancebo MC, Eisen JL, et al. The Brown Longitudinal Obsessive Compulsive Study: clinical features and symptoms of the sample at intake. J Clin Psychiatry. 2006;67(5):703-711.
24. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (SCID/IP Version 2.0). New York: Biometrics Research Department, New York State Psychiatric Institute; 1996.
25. Pinto A, Eisen JL, Mancebo MC, et al. Taboo thoughts and doubt/checking: a refinement of the factor structure for obsessive-compulsive disorder symptoms. Psychiatry Res. 2007;151(3):255-258.
26. Pinto A, Greenberg BD, Grados MA, et al. Further development of YBOCS dimensions in the OCD Collaborative Genetics study: symptoms vs categories. Psychiatry Res. 2008;160(1):83-93.
27. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale, II: validity. Arch Gen Psychiatry. 1989;46(11):1012-1016.
28. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive-Compulsive Scale, I: development, use and reliability. Arch Gen Psychiatry. 1989;46(11):1006-1011.
29. Eisen JL, Phillips KA, Baer L, et al. The Brown Assessment of Beliefs Scale: reliability and validity. Am J Psychiatry. 1998;155(1):102-108.
30. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision.Washington, DC: American Psychiatric Press; 2000.
31. Keller MB, Lavori PW, Friedman B, et al. The Longitudinal Interval Follow-up Evaluation: a comprehensive method for assessing outcome in prospective longitudinal studies. Arch Gen Psychiatry. 1987;44(6):540-548.
32. Warshaw MG, Keller MB, Stout RL. Reliability and validity of the Longitudinal Interval Follow-Up Evaluation for assessing outcome of anxiety disorders. J Psychiatr Res. 1994;28(6):531-545.
33. SAS [computer program]. Version 9.1.3. Cary, NC: SAS Institute; 2007.
34. Cox R. Regression models and life-tables. J R Stat Soc Ser B. 1972;34:187-220.
35. March JS, Frances A, Carpenter D, et al. The expert consensus guidelines series: treatment of obsessive-compulsive disorder. J Clin Psychiatry. 1997;58(suppl 4):1-72.
36. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder. Am J Psychiatry. 2007;164(suppl 7):1-56.
37. Phillips KA, Pagano ME, Menard W, et al. A 12-month follow-up study of the course of body dysmorphic disorder. Am J Psychiatry. 2006;163(5):907-912.
38. Keller MB, Lavori PW, Coryell W, et al. Bipolar I: a five-year prospective follow-up. J Nerv Ment Dis. 1993;181(4):238-245.
39. Yonkers KA, Bruce SE, Dyck IR, et al. Chronicity, relapse, and illness - course of panic disorder, social phobia, and generalized anxiety disorder: findings in men and women from 8 years of follow-up. Depress Anxiety. 2003;17(3):173-179.
40. Pauls DL, Alsobrook JP 2nd, Goodman WK, et al. A family study of obsessive-compulsive disorder. Am J Psychiatry. 1995;152(1):76-84.
41. Ravizza L, Barzega G, Bellino S, et al. Predictors of drug treatment response in obsessive-compulsive disorder. J Clin Psychiatry. 1995;56(8):368-373.
42. Bogetto F, Venturello S, Albert U, et al. Gender-related clinical differences in obsessive-compulsive disorder. Eur Psychiatry. 1999;14(8):434-441.
43. Steketee G, Frost R. Compulsive hoarding: current status of the research. Clin Psychol Rev. 2003;23(7):905-927.
44. Black DW, Monahan P, Gable J, et al. Hoarding and treatment response in 38 nondepressed subjects with obsessive-compulsive disorder. J Clin Psychiatry. 1998;59(8):420-425.
45. Abramowitz JS, Franklin ME, Schwartz SA, et al. Symptom presentation and outcome of cognitive-behavioral therapy for obsessive-compulsive disorder. J Consult Clin Psychol. 2003;71(6):1049-1057.
46. Saxena S, Brody AL, Maidment KM, et al. Paroxetine treatment of compulsive hoarding. J Psychiatr Res. 2007;41(6):481-487.
47. Storch EA, Merlo LJ, Larson MJ, et al. Symptom dimensions and cognitive-behavioural therapy outcome for pediatric obsessivecompulsive disorder. Acta Psychiatr Scand. 2008;117(1):67-75.